@article{a9e35e60622c4a90962f71ee8e7bbafb,
title = "Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, non-neutropenic, adult patients: An update including COVID-19 data",
author = "{FUNDICU investigators (collaborators)} and Matteo Bassetti and Valentina Zuccaro and Erika Asperges and Luigia Scudeller and Giacobbe, {Daniele Roberto} and M. Akova and A. Alastruey-Izquierdo and S. Arikan-Akdagli and E. Azoulay and S. Blot and A. Cortegiani and Cornely, {O. A.} and C. Grecchi and C. Lass-Fl{\"o}rl and P. Koehler and M. Cuenca-Estrella and {de Lange}, {D. W.} and {De Rosa}, {F. G.} and {De Waele}, {J. J.} and G. Dimopoulos and J. Garnacho-Montero and M. Hoenigl and Kanj, {S. S.} and F. Lamoth and J. Maertens and I. Martin-Loeches and P. Mu{\~n}oz and Kullberg, {B. J.} and C. Agvald-Ohman and G. Poulakou and C. Rebuffi and J. Rello and M. Sanguinetti and Taccone, {F. S.} and Timsit, {J. F.} and A. Torres and Vazquez, {J. A.} and J. Wauters and T. Calandra and S. Tejada and I. Karaiskos and M. Peghin and A. Vena and Mortensen, {K. L.} and C. Lebihan and T. Mercier",
note = "Funding Information: Outside the submitted work, DRG reports investigator-initiated grants from Pfizer, Shionogi, and Gilead Italia, and speaker and/or advisory board fees from Pfizer and Tillotts Pharma. Outside the submitted work, MB reports research grants and/or advisor/consultant and/or speaker/chairman fees from Bayer, BioM{\'e}rieux, Cidara, Cipla, Gilead, Menarini, MSD, Pfizer, and Shionogi. The other authors have no conflict of interests to disclose. ",
year = "2022",
month = nov,
doi = "10.1016/j.jinf.2022.08.003",
language = "English (US)",
volume = "85",
pages = "573--607",
journal = "Journal of Infection",
issn = "0163-4453",
publisher = "W.B. Saunders Ltd",
number = "5",
}
